Safety of allogenic mesenchymal stem cells derived exosome on disability of patients with acute ischaemic stroke: a randomised, open labled, placebo-controlled, phase 1 trial

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 5 人开始时间: 待定最近更新: 2020年11月30日

试验速览

暂无简介。

•Male acute ischemic patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset.
•Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement
•Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study.
•Patients must have a score on the NIH Stroke Scale 8-24,
•Obtaining informed consent signed

•Comatose patients.
•brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage.
•alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis
•patients with dementia
•Specify clinical conditions
•Patients who are participating in another clinical trial.
•Inability or unwillingness of individual for giving written informed consent.

发起方